# EDGAR Filing Document

**Accession Number:** 0001159036
**File Stem:** 0001159036-26-000035
**Filing Date:** 2026-3
**Character Count:** 14508
**Document Hash:** 721dcc7acf40d63607d1d5c82c2cb033
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001159036-26-000035.hdr.sgml**: 20260312

**ACCESSION NUMBER**: 0001159036-26-000035

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 15

**CONFORMED PERIOD OF REPORT**: 20260312

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260312

**DATE AS OF CHANGE**: 20260312

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** HALOZYME THERAPEUTICS, INC.
- **CENTRAL INDEX KEY:** 0001159036
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 880488686
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-32335
- **FILM NUMBER:** 26745773

**BUSINESS ADDRESS:**
- **STREET 1:** 12390 EL CAMINO REAL
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92130
- **BUSINESS PHONE:** (858) 794-8889

**MAIL ADDRESS:**
- **STREET 1:** 12390 EL CAMINO REAL
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92130

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** HALOZYME THERAPEUTICS INC
- **DATE OF NAME CHANGE:** 20040312

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** GLOBAL YACHT SERVICES INC
- **DATE OF NAME CHANGE:** 20010912

?xml version='1.0' encoding='ASCII'? halo-20260312

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**____________________________________________**

**FORM 8-K** 

**_____________________________________________**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934**

---

| | |
|:---|:---|
| **Date of Report (Date of Earliest Event Reported):** | **March 12, 2026** |

---

![Halo Logo updated.jpg](halo-20260312_g1.jpg)

**HALOZYME THERAPEUTICS, INC.** 

**(Exact name of registrant as specified in its charter)**

**________________________**

**Commission File Number 001-32335** 

---

| | |
|:---|:---|
| **Delaware** | **88-0488686** |
| *(State or other jurisdiction of incorporation)* | *(I.R.S. Employer Identification No.)* |
| **12390 El Camino Real** | **92130** |
| **San Diego** | *(Zip Code)* |
| **California** | |
| *(Address of principal executive offices)* | |

---

**(858) 794-8889** 

*(Registrant's telephone number, including area code)*

**Not Applicable**

*(Former name or former address, if changed since last report)*

**________________________**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| Common Stock, $0.001 par value | HALO | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

(c) On March 12, 2026, Halozyme Therapeutics, Inc. (the "Company") announced that David Ramsay has been appointed to serve as the Company's Interim Chief Financial Officer ("Interim CFO"), effective March 23, 2026. Since April 2017, Mr. Ramsay (age 61) has served as a member of the Board of Directors of Savara Inc., a clinical-stage biopharmaceutical company focused on rare respiratory diseases. Since 2017, he has also served on the board of directors of Exuma Biotech, Inc., a privately held biotechnology company. Mr. Ramsay served as Senior Vice President and Chief Financial Officer of Bonti, Inc., a private, clinical stage biotechnology company focused on the development and commercialization of neurotoxin products for therapeutic and aesthetic applications, from February 2018 until its acquisition by Allergan plc in October 2018. Mr. Ramsay previously served as the Company's Chief Financial Officer from 2003 to 2009 and from 2013 until 2015. He also served as the Company's Vice President, Corporate Development from 2009 to 2013. Mr. Ramsay began his career at Deloitte & Touche, where he obtained his CPA license. Mr. Ramsay holds a B.S. in business administration from the University of California, Berkeley and an M.B.A. with a dual major in finance and strategic management from The Wharton School at the University of Pennsylvania.

There are no family relationships between Mr. Ramsay and any director, executive officer or person nominated or chosen by the Company to become a director or executive officer. Mr. Ramsay does not have a direct or indirect material interest in any transaction or arrangement in which the Company is a participant.

In his role as Interim CFO, Mr. Ramsay will be paid a monthly salary of $50,000. Mr. Ramsay will also receive an equity grant consisting of 10,000 restricted stock units ("RSUs") that will vest on June 30, 2026, provided he remains employed with the Company through such date, and be subject to a one-year holding period from the vesting date. In the event Mr. Ramsay continues to serve as Interim CFO on July 1, 2026, he will be granted an additional 2,500 RSUs which will vest on his employment termination date and be subject to a one-year holding period from the vesting date. The RSUs will be granted under, and be subject to the terms and conditions of, the Company's 2021 Stock Plan.

On March 12, 2026, the Company issued a press release announcing the appointment of Mr. Ramsay as Interim CFO. A copy of the press release is attached hereto as Exhibit 99.1.

**Item 9.01 Financial Statements and Exhibits.**

Exhibits

---

| | |
|:---|:---|
| <u>Exhibit No.</u> | <u>Description</u> |
| <u>[99.1](davidramsaypressreleasefin.htm)</u> | Press Release of Halozyme Therapeutics, Inc. dated March 12, 2026 |
| 104 | Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101) |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
| | | | Halozyme Therapeutics, Inc.<br>(Registrant) |
| Dated: | March 12, 2026 | By: | */s/ Mark Snyder* |
|  |  |  | Mark Snyder |
|  |  |  | Senior Vice President, General Counsel and Corporate Secretary |

---

## Exhibit 99.1

**Exhibit 99.1**![image_0a.jpg](image_0a.jpg)

**Halozyme Appoints David Ramsay as Interim Chief Financial Officer**

**SAN DIEGO, March 12, 2026** -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today announced that David Ramsay has been appointed Interim Chief Financial Officer (CFO), effective March 23, 2026. Mr. Ramsay will oversee all financial operations while the company continues its active search for a permanent CFO.

Mr. Ramsay brings more than 30 years of strategic financial leadership across the biotechnology and life sciences sectors, including extensive experience in capital markets, corporate finance, investor relations, and operational scale-up. He previously served as Halozyme's Chief Financial Officer from 2003 to 2009 and again from 2013 to 2015, during which time the company evolved from a private enterprise to a billion-dollar public biopharmaceutical company.

During his prior tenure as CFO, Mr. Ramsay guided the company through significant growth and played a key role in establishing Halozyme's foundational financial and technology commercialization infrastructure. Previously, Mr. Ramsay served as Senior Vice President and Chief Financial Officer of Bonti, Inc. until its sale to Allergan plc in October 2018.

"I am thrilled to have the opportunity to work with David again," said Dr. Helen Torley, President and Chief Executive Officer. "His deep understanding of Halozyme, combined with his exceptional capital markets expertise, investor expertise and credibility, and his longstanding record of financial leadership, makes him an invaluable partner as we advance our strategic priorities. David has made a lasting impact on Halozyme's evolution, and we are fortunate to welcome him back into a role where his experience and leadership will be immediately impactful."

The company's executive search for a permanent Chief Financial Officer is well underway and progressing. Halozyme has engaged a leading executive search firm to identify candidates who bring the combination of capital markets expertise and strategy. Mr. Ramsay will remain in the role until a permanent CFO is appointed.

Mr. Ramsay holds a B.S. in business administration from the University of California, Berkeley and an M.B.A. with a dual major in finance and strategic management from The Wharton School at the University of Pennsylvania.

------

**About Halozyme**

Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE<sup>®</sup> drug delivery technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution facilitates the subcutaneous delivery of injected drugs and fluids, reducing treatment burden and improving convenience. ENHANZE<sup>®</sup> has touched more than one million patient lives through ten commercialized products across over 100 global markets and is licensed to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical, Acumen Pharmaceuticals, Merus N.V. and Skye Bioscience.

Halozyme expanded its drug delivery technology portfolio to develop partner products using Hypercon™ and Surf Bio's hyperconcentration technology. Hypercon™ is an innovative microparticle technology expected to set a new standard in hyperconcentration of drugs and biologics by reducing injection volume for the same dosage and enabling administration in at-home and healthcare-provider settings. The addition of Surf Bio's polymer-based hyperconcentration technology further broadens the range of biologics that can be delivered subcutaneously, meaningfully expanding the scope of opportunities across therapeutic modalities. Together, Hypercon™ and Surf Bio's technology complement ENHANZE<sup>®</sup> by enabling creation and delivery of highly concentrated biologics. The Hypercon™ technology has been licensed to leading biopharmaceutical partners, including Janssen, Eli Lilly and argenx.

Halozyme also develops, manufactures and commercializes drug-device combination products using advanced auto-injector technologies designed to improve convenience, reliability and tolerability, enhancing patient comfort and adherence. The Company has two proprietary commercial products, Hylenex<sup>®</sup> and XYOSTED<sup>®</sup>, partnered commercial products and ongoing development programs with Teva Pharmaceuticals and McDermott Laboratories Limited, an affiliate of Viatris Inc.

Halozyme is headquartered in San Diego, CA, with offices in Ewing, NJ; Minnetonka, MN; and Boston, MA. Minnetonka is also the site of its operations facility.

For more information, visit www.halozyme.com and connect with us on LinkedIn.

------

**Forward-Looking Statements**

This press release may include forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts and may include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential and statements regarding Halozyme's executive search efforts for a permanent chief executive officer, future performance and growth of Halozyme's business. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans", "will be" and similar expressions. Although Halozyme believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Halozyme, that could cause actual results and developments to differ materially from those expressed in the forward-looking information and statements. Actual results could differ materially from the expectations contained in these forward-looking statements as a result of several factors, including potential delays in hiring a permanent chief financial officer. These and other factors that may result in differences are discussed in greater detail in the Company's most recently filed Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission. Halozyme undertakes no obligation to update or revise any forward-looking statements or any other information contained herein.

**Contacts:** 

Tram Bui

VP, Investor Relations and Corporate Communications

609-333-7668

<u>tbui@halozyme.com</u>

Sydney Charlton

Teneo

917-972-8407

<u>sydney.charlton@teneo.com</u>

<br>